A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?.

Schlick, K, Troch, M, Placher-Sorko, G, Faber, V, Neureiter, D, Berghoff, AS, Preusser, M, Greil, R, Hopfinger, G. Ann Hematol. 2015, 94(2): 345-346.

Adipocyte-derived players in hematologic tumors: useful novel targets?.

Jöhrer, K, Ploner, C, Thangavadivel, S, Wuggenig, P, Greil, R. Expert Opin Biol Ther. 2015, 15(1): 61-77.

A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and ОІ2 -microglobulin.

Melchardt, T, Troppan, K, Weiss, L, Hufnagl, C, Neureiter, D, Tränkenschuh, W, Hopfinger, G, Magnes, T, Deutsch, A, Neumeister, P, Hackl, H, Greil, R, Pichler, M, Egle, A. Br J Haematol. 2015, 168(2):239-245.

B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.

Zaborsky, N, Holler, C, Geisberger, R, Asslaber, D, Gassner, FJ, Egger, V, PiГ±Гіn-Hofbauer, J, Kocher, T, Hartmann, TN, Greil, R, Egle, A. Haematologica. 2015, 100(8): e307-e310.

Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.

Kern, D, Regl, G, Hofbauer, SW, Altenhofer, P, Achatz, G, Dlugosz, A, Schnidar, H, Greil, R, Hartmann, TN, Aberger, F. Oncogene. 2015, 34(42): 5341-5351.

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms.

Hutterer, E, Asslaber, D, Caldana, C, Krenn, PW, Zucchetto, A, Gattei, V, Greil, R, Hartmann, TN. Br J Haematol. 2015, 169(2):286-289.

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

Them, NC, Bagienski, K, Berg, T, Gisslinger, B, Schalling, M, Chen, D, Buxhofer-Ausch, V, Thaler, J, Schloegl, E, Gastl, GA, Wolf, D, Strecker, K, Egle, A, Melchardt, T, Burgstaller, S, Willenbacher, E, Zagrijtschuk, O, Klade, C, Greil, R, Gisslinger, H, Kralovics, R. Am J Hematol. 2015, 90(4): 288-294.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin“s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Behringer, K, Goergen, H, Hitz, F, Zijlstra, JM, Greil, R, Markova, J, Sasse, S, Fuchs, M, Topp, MS, Soekler, M, Mathas, S, Meissner, J, Wilhelm, M, Koch, P, Lindemann, H, Schalk, E, Semrau, R, Kriz, J, Vieler, T, Bentz, M, Lange, E, Mahlberg, R, Hassler, A, Vogelhuber, M, Hahn, D, Mezger, J, Krause, SW, Skoetz, N, Böll, B, von Tresckow, B, Diehl, V, Hallek, M, Borchmann, P, Stein, H, Eich, H, Engert, A. Lancet. 2015, 385(9976):1418-1427.

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Knauer, M, Moik, M, Jakesz, R, Seifert, M, Taucher, S, Bjelic-Radisic, V, Balic, M, Eidtmann, H, Eiermann, W, Steger, G, Kwasny, W, Dubsky, P, Selim, U, Fitzal, F, Hochreiner, G, Wette, V, Sevelda, P, Ploner, F, Bartsch, R, Fesl, C, Greil, R. Ann Oncol. 2015, 26(2):313-320.

Lapatinib-plus-Pegylated Liposomal Doxorubicin in Advanced HER2-positive Breast Cancer Following Trastuzumab: A Phase II Trial.

Pircher, M, Mlineritsch, B, Fridrik, MA, Dittrich, C, Lang, A, Petru, E, Weltermann, A, Thaler, J, Hufnagl, C, Gampenrieder, SP, Rinnerthaler, G, Ressler, S, Ulmer, H, Greil, R. Anticancer Res. 2015, 35(1): 517-521.